Skip to free case review
Suboxone Film • Dental Injury Claims • MDL 3092 • Updated August 2026

Suboxone Lawsuit 2026: MDL 3092 Tooth Decay & Bellwether Update

Suboxone lawsuit claims allege that Suboxone buprenorphine/naloxone film can contribute to dental erosion, tooth decay and related dental damage when it dissolves in the mouth, and that adequate warnings were not provided during relevant periods. Federal cases are centralized in MDL 3092 in the Northern District of Ohio before Judge J. Philip Calabrese, and defendants dispute liability and individualized causation.

Quick answer: The August 3, 2026 JPML report lists 1,827 actions pending and 1,908 historical actions in Suboxone Film MDL 3092. The current bellwether protocol places 50 Core Discovery Pool cases in a deposition period running through January 15, 2027, with a 15-case Trial Pool scheduled for selection on January 29, 2027. FDA requires dental-risk warnings for buprenorphine medicines that dissolve in the mouth, while emphasizing that the benefits of buprenorphine treatment for opioid use disorder generally outweigh these dental risks.
1,827 PendingMDL 3092 actions as of Aug. 3, 2026
50 Core CasesCore Discovery Pool depositions underway
Jan. 29, 2027Scheduled 15-case Trial Pool selection
No Global PayoutNo court-approved universal settlement matrix
Last reviewedAugust 20, 2026
Source standardCourt, JPML & FDA first
PurposeEducational information only
Start Here

Choose the Suboxone Lawsuit Information You Need

Start with potential eligibility or current MDL status, then review dental injuries, evidence, settlement factors or the calculator.

Primary sourcesCourt, JPML, FDA
2026 statusDated MDL facts
Clear intentGuide → calculator → settlement research
Lawsuit Overview

What Is the Suboxone Tooth Decay Lawsuit About?

The current federal personal-injury litigation focuses on Suboxone buprenorphine/naloxone film and alleged dental erosion and decay. The Northern District of Ohio describes plaintiffs' common allegations as involving the film's alleged acidity, prolonged contact while dissolving in the mouth, dental injury and the adequacy of testing and warnings. These allegations remain disputed.

Product claim

Suboxone Film

MDL 3092 specifically concerns Suboxone buprenorphine/naloxone film products-liability claims, not every form of buprenorphine treatment.

Injury focus

Dental Erosion & Decay

Plaintiffs allege tooth decay, erosion and other dental damage after use of film that dissolves in the mouth.

Defense position

Liability Is Disputed

Individual cases can involve disputes over warnings, product use, dental baseline, causation, alternative causes, damages and filing deadlines.

Separate legal tracks: older antitrust, pricing and government matters involving Suboxone are different from the current MDL 3092 personal-injury litigation. This page focuses on dental-injury products-liability claims.
Potential Eligibility

Who May Qualify for a Suboxone Lawsuit?

There is no single public use-duration or procedure threshold that automatically determines legal eligibility. A claim-specific review generally considers use of Suboxone film, dental condition before and during treatment, injury timing, dental procedures, alternative causes, product records and applicable state law.

Suboxone Film Use

  • Prescription, pharmacy or treatment-program records identifying Suboxone film.
  • Approximate treatment dates, dose and duration.
  • Use occurring before the claimed dental deterioration.

Documented Dental Injury

  • New or worsening tooth decay or cavities.
  • Dental erosion, fractured teeth or repeated restorative treatment.
  • Infections, extractions, crowns, root canals, implants, bridges or dentures.

Dental Baseline & Causation

Prior dental records, hygiene history, tobacco use, dry mouth, diet, other medications and preexisting disease can matter when evaluating alternative causes and changes over time.

Damages & Deadlines

Treatment costs, future reconstruction, pain, functional limitations, lost income and state-specific filing rules may affect the legal and economic analysis.

Do not stop Suboxone because of lawsuit information: FDA states that patients should continue buprenorphine as prescribed and should not suddenly stop it without consulting a healthcare professional because withdrawal, relapse, overdose and death are possible consequences.
Federal Litigation

Suboxone MDL 3092 Status and Bellwether Schedule

In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092, is centralized before Judge J. Philip Calabrese in the Northern District of Ohio. The August 3, 2026 JPML report lists 1,827 pending actions and 1,908 historical actions.

1,827pending actions as of Aug. 3, 2026
50 casesCore Discovery Pool
Jan. 15, 2027scheduled end of Core Discovery depositions
Jan. 29, 2027scheduled 15-case Trial Pool selection

February 5, 2024 — MDL Centralized

JPML centralized federal Suboxone film dental-injury cases in the Northern District of Ohio.

March 27, 2026 — Bellwether Protocol Updated

The court entered Second Amended Case Management Order No. 15 with specific Core Discovery and Trial Pool dates.

July 13, 2026–January 15, 2027 — Core Depositions

The protocol schedules depositions for the 50 Core Discovery Pool cases during this period, subject to its stated holiday blackout.

July 16, 2026 — Provider Depositions

Case Management Order No. 23 governs provider depositions in Core Discovery Pool cases.

January 29, 2027 — Trial Pool

The protocol schedules a 15-case Trial Pool: five chosen by plaintiffs, five by defendants and five randomly selected.

March 2028 — Proposed First Trial Setting

Exhibit A lists March 2028 as a proposed first-trial setting, but the court states that this later schedule will be reduced to a future order.

FDA Dental Safety Warning

What the FDA Says About Buprenorphine Dental Problems

In January 2022, FDA warned that dental problems had been reported with buprenorphine-containing medicines dissolved in the mouth. Reported problems included tooth decay, cavities, oral infections and tooth loss, including cases in people with no previous dental problems. FDA required a new dental-risk warning in prescribing information and Medication Guides.

305 reports

Dental Cases Reviewed

FDA identified 305 reported dental cases, including 131 classified as serious.

113 reports

Multiple Teeth Affected

FDA stated that 113 reports mentioned two or more affected teeth.

71 reports

Extractions

Tooth extraction/removal was the most commonly reported treatment in the cases FDA summarized.

~2 years

Median Time to Diagnosis

FDA reported a median time of approximately two years from starting treatment to diagnosis among the cases reviewed.

Medical safety: FDA says the benefits of buprenorphine treatment clearly outweigh the dental risks for opioid use disorder. Patients should not abruptly discontinue treatment.
Claimed Dental Injuries

Tooth Decay, Erosion, Infection and Tooth Loss Claims

MDL 3092 centers on allegations of dental erosion and decay associated with Suboxone film. FDA's broader transmucosal-buprenorphine warning also describes cavities, infection, erosion and tooth loss among reported dental events.

Tooth Decay & Cavities

New or rapidly progressing caries may lead to fillings, crowns or more extensive treatment.

Dental Erosion & Fractures

Loss of enamel or structure may contribute to sensitivity, cracking or broken teeth.

Infection & Root Canals

Deep decay or infection can require endodontic treatment, antibiotics or extraction.

Tooth Loss & Reconstruction

Severe injury may involve extractions, implants, bridges, dentures or bone grafting.

Product Scope

Suboxone Film vs. Other Buprenorphine Medicines

The current federal MDL is specifically titled Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation. FDA's 2022 dental warning is broader and addresses buprenorphine-containing tablets and films dissolved under the tongue or against the inside of the cheek. FDA said it had not identified the same dental concern for routes such as patches and injections in that communication.

Product / RouteFDA Dental Warning ContextMDL 3092 Context
Suboxone filmBuprenorphine/naloxone film dissolved in the mouth falls within FDA's transmucosal warning.Central product at issue in MDL 3092.
Other buprenorphine films/tablets dissolved in mouthFDA warning applies broadly to buprenorphine medicines dissolved in the mouth.Do not assume every product is automatically part of MDL 3092; product-specific legal review is needed.
Patch / injection routesFDA said it had not identified a dental-health concern related to these routes in its 2022 communication.Not the central Suboxone film exposure described by the MDL court page.
Claim Documentation

Evidence Commonly Reviewed in a Suboxone Dental Injury Claim

Prescription Proof

Pharmacy records, MAT clinic records, prescriber notes and insurance claims identifying Suboxone film and treatment dates.

Baseline Dental Records

Dental exams, X-rays and treatment history from before or early in treatment can help establish prior condition.

Injury & Procedure Records

Dental charts, X-rays, treatment plans, root canals, crowns, extraction notes, implants and dentures.

Damages Records

Paid bills, future treatment estimates, travel expenses, missed work and evidence of functional limitations.

Settlement Research

Suboxone Lawsuit Settlement Status and Value Factors

There is no court-approved global Suboxone dental-injury settlement or verified average payout in MDL 3092. The litigation is still developing representative cases through bellwether discovery. Any TortAdvisor dollar ranges are educational planning models rather than official settlement amounts, offers or guarantees.

Confirmed vs. estimated: the MDL case count, court schedule and FDA warning are source-backed facts. Individual claim value remains unknown and can depend on injury severity, treatment, product proof, causation, defenses, state law and any future settlement terms.

Number of Teeth Affected

Limited decay and widespread multi-tooth injury can create different treatment burdens.

Dental Procedures

Fillings, crowns, root canals, extractions, implants, dentures and reconstruction may affect damages.

Future Dental Care

Replacement restorations, implant maintenance and future treatment can matter when supported.

Baseline Dental Condition

Prior decay, periodontal disease and other conditions can affect causation and damages arguments.

Product & Timing Evidence

Reliable proof of Suboxone film use and a documented timeline can be important.

Legal Defenses & Deadlines

Warnings, causation, statutes of limitation and jurisdiction can affect value or viability.

Claim Process

How a Suboxone Dental Injury Claim May Be Evaluated

1

Confirm Film Use

Identify prescriptions, treatment dates, dose and pharmacy or program records.

2

Establish Dental Baseline

Gather earlier dental records and imaging where available.

3

Document Injury

Collect records showing decay, erosion, infection, fractures and procedures.

4

Review Causation

Evaluate timing, alternative causes, warnings and defendant-specific evidence.

5

Check Filing Rules

Review state statutes, discovery rules, venue and MDL requirements.

6

Document Damages

Preserve bills, future treatment plans, wage loss and other supported losses.

Filing Deadlines

Suboxone Lawsuit Statute of Limitations

There is no single nationwide filing deadline for every Suboxone dental injury claim. Product-liability statutes of limitation and repose vary by state, and the start date can depend on dental diagnosis, discovery of a possible connection, prescription history, product use, warnings, residence and other facts.

Do not rely on a generic deadline: a missed statute of limitations may bar a claim. Anyone concerned about timing should obtain jurisdiction-specific legal advice promptly rather than waiting for a bellwether trial or settlement announcement.
Frequently Asked Questions

Suboxone Lawsuit FAQ

How many Suboxone lawsuits are pending?

JPML's August 3, 2026 report lists 1,827 actions pending and 1,908 historical actions in MDL 3092.

What injuries are central to MDL 3092?

The Northern District of Ohio describes allegations that Suboxone film can cause dental erosion and decay and that dental warnings were inadequate.

Did FDA issue a Suboxone dental warning?

FDA issued a 2022 warning for buprenorphine medicines dissolved in the mouth, including combination products such as Suboxone, and required new dental-risk warnings.

Should someone stop taking Suboxone because of dental concerns?

No one should abruptly stop prescribed buprenorphine based on lawsuit information. FDA warns that sudden discontinuation can cause withdrawal and increase the risk of relapse, overdose and death.

Has there been a global Suboxone tooth decay settlement?

No court-approved universal Suboxone dental-injury settlement or payout matrix has been established in MDL 3092 as of this update.

What is happening with bellwether cases?

The current protocol places 50 Core Discovery Pool cases in depositions through January 15, 2027 and schedules selection of a 15-case Trial Pool on January 29, 2027.

What records can help a Suboxone dental claim?

Prescription records, pharmacy or treatment-program records, pre-treatment dental records, later dental charts and X-rays, procedure records, bills and future treatment plans can all be relevant.

Is every buprenorphine product part of MDL 3092?

No. MDL 3092 is specifically the Suboxone buprenorphine/naloxone film products-liability litigation. FDA's dental warning is broader and covers buprenorphine medicines dissolved in the mouth.

Primary Sources

Suboxone Lawsuit Sources and Official References

  1. U.S. District Court for the Northern District of Ohio — MDL 3092. Official court page identifying the judge, litigation description and current orders.
  2. Judicial Panel on Multidistrict Litigation — Pending MDL Reports. August 3, 2026 report lists 1,827 pending and 1,908 historical actions in MDL 3092.
  3. Second Amended Case Management Order No. 15. March 27, 2026 bellwether protocol with Core Discovery and Trial Pool schedule.
  4. FDA — Dental problems with buprenorphine medicines dissolved in the mouth. January 12, 2022 Drug Safety Communication.
Next Step

Request a Confidential Suboxone Dental Injury Case Review

If you used Suboxone film and later developed significant dental decay, erosion, tooth loss or related treatment needs, submit the prescription, dental injury and treatment information you know now for review.

Legal and medical disclaimer: TortAdvisor.com is not a law firm and does not provide legal or medical advice. Lawsuit allegations are disputed unless and until established through settlement, judgment or another binding resolution. This page does not guarantee eligibility, representation, compensation or any outcome. Do not stop or change Suboxone or another buprenorphine medicine because of lawsuit information. FDA states that abruptly stopping prescribed buprenorphine can cause serious consequences, including withdrawal, relapse, overdose and death. Discuss treatment and dental-care decisions with licensed healthcare professionals. Submitting information does not create an attorney-client relationship.